CinRx Pharma
Hub & spoke biotech featuring a novel, combination approach to obesity
Key Highlights
- Combination approach to obesity treatment:CinRx portfolio company CinFina is advancing four first-in-class obesity medicines with potential to achieve improved tolerability and efficacy than currently available GLP-1s. The combination of its two gut peptide monotherapies work centrally to reduce appetite and require less frequent dosing, and the two dual-agonists aim to alter metabolism and improve standard of care when combined with GLP-1 therapies.
- A “hub and spoke” model: CinRx’s portfolio of CinCos are centrally funded and managed by a team of scientific, technical, and drug development experts with decades of experience. This enables nimble decision-making and resource allocation, with value at each individual company, which de-risks buy-in from investors. The model’s success was proven in January 2023 when former portfolio company, CinCor, was acquired by AstraZeneca for $1.8 billion. Among CinRx’s leading CinCos are CinFina, CinDome and CinPhloro.
- Recent milestones: In March 2024, CinFina announced the dosing of the first patients in its Phase 1 trial of CIN-110. Upcoming milestones include anticipated Phase 2 data evaluating CIN-109 with and without semaglutide in 2024 and Investigational New Drug (IND) application submissions for CIN-209 and CIN-210. In February 2024, CinPhloro dosed the first patients in the Phase 2 enviva study to evaluate the safety, efficacy and tolerability of CIN-103 for IBS-D, and initial data is expected later this year.
- CinRx Chief Business Officer Gavin Samuels is participating in a panel titled A Licensing Deal for All Seasons on Monday, June 3 at 1:45 PM.